Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A
Theo nguồn tin Sangamo BioSciences trên trang mạng của prnewswire.com SB-525 is one of four programs in the Company’s newly focused clinical portfolio of in vivo genomic therapies for rare…